#United States #San Francisco #Henlius #JPM 2026 #Globalization 2.0

Henlius Introduces Globalization 2.0 Strategy at JPM 2026

The 44th J.P. Morgan Healthcare Conference was a remarkable gathering of the healthcare industry, held in San Francisco from January 12 to 15, 2026. On January 15, Dr. Jason Zhu, the CEO of Shanghai Henlius Biotech, Inc., delivered a pivotal keynote presentation outlining the company's "Globalization 2.0" strategy alongside its medium- to long-term innovation roadmap.

In his presentation, Dr. Zhu noted that Henlius is experiencing robust international growth, with expectations to launch over 20 products globally by 2030, including more than 15 in the U.S. and European markets. This ambitious target reflects the company's commitment to increasing its global footprint and diversifying its portfolio.

Key Highlights from the Presentation

Dr. Zhu emphasized Henlius's consistent growth trajectory and gradual achievements under the "Globalization 2.0" framework. He stated, _"With multiple product approvals in Europe and the United States, our global operating model has matured significantly, sustaining our international growth momentum. Our integrated R&D, regulatory, and manufacturing capabilities, along with a strengthening clinical and commercial network, empower us to continuously deliver innovative assets worldwide."

He further explained that stable cash flows from the company’s biosimilar portfolio will significantly boost investments in innovation over the coming five years. This will facilitate the advancement of differentiated molecules such as Antibody-Drug Conjugates (ADC), multi-specific antibodies, and T-cell engagers (TCE) in global markets. Dr. Zhu envisions building a sustainable and replicable global growth model through these efforts.

The presentation also detailed clear timelines and developmental plans for Henlius's key innovative assets slated for 2026. They include:

• - Serplulimab (marketed as Hetronifly® in Europe): An anti-PD-1 monoclonal antibody.
• - HLX22: A novel anti-HER2 monoclonal antibody.
• - HLX43: A PD-L1 ADC.
• - HLX07: An anti-EGFR monoclonal antibody.

Diverse Pipeline of Preclinical Assets

Henlius's preclinical asset portfolio encompasses various molecular modalities, focusing primarily on solid tumors. The company's differentiated development strategy targets both established and emerging therapeutic targets such as PD-(L)1, DLL3, B7-H3, HER2, EGFR, c-Met, and KAT6A/B. Their portfolio aims to maintain a balanced mix of potential First-In-Class (FIC) and Best-In-Class (BIC) candidates while also pursuing rapid follow-up programs that hold strong clinical and commercial viability.

This structured approach not only showcases Henlius’s dedication to cutting-edge innovations but also highlights their commitment to managing developmental efficiency and risk. The company has crafted a tiered R&D architecture designed to ensure continuous progress of its innovative product pipeline.

Looking Ahead

As Henlius forges ahead with its "Globalization 2.0" vision, the company's robust plans signal a promising future for the biotech industry. The commitment to innovate and expand in international markets underlines Henlius's ambition to be a leading player in the global healthcare arena.

In conclusion, as Henlius continues to develop its strategies, the future looks bright for both the company and the global biopharmaceutical landscape, marking a significant milestone in the journey towards delivering quality healthcare innovations to patients worldwide.